Cytokinetics (CYTK) News Today $45.74 -1.25 (-2.66%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Cytokinetics: Strategic Vision 2030 and Financial Readiness Strengthen Buy RatingJanuary 15, 2025 | markets.businessinsider.comCytokinetics: Promising Drug Pipeline and Strategic Vision Drive Buy RatingJanuary 14, 2025 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Cytokinetics (CYTK)January 14, 2025 | markets.businessinsider.comCytokinetics (NASDAQ:CYTK) Receives Market Outperform Rating from JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and set a $78.00 price objective on shares of Cytokinetics in a research note on Tuesday.January 14, 2025 | marketbeat.comCautious Hold on Cytokinetics Amid Regulatory Uncertainties and Distant MilestonesJanuary 14, 2025 | markets.businessinsider.comCytokinetics CEO not looking to be bought, but would listen, STAT saysJanuary 13, 2025 | markets.businessinsider.comCytokinetics’ Promising Future: Aficamten Approval and Robust Pipeline Drive Growth ProspectsJanuary 13, 2025 | markets.businessinsider.comCytokinetics, Incorporated: Cytokinetics Announces 2025 Corporate Milestones and Vision 2030January 13, 2025 | finanznachrichten.deCytokinetics provided milestones expected in 2025January 13, 2025 | markets.businessinsider.comCytokinetics Announces 2025 Corporate Milestones and Vision 2030January 13, 2025 | globenewswire.comCytokinetics' (CYTK) Buy Rating Reiterated at HC WainwrightJanuary 13, 2025 | americanbankingnews.comFady Ibraham Malik Sells 2,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockJanuary 11, 2025 | insidertrades.comAficamten Poised for Best-in-Class Status in oHCM Treatment with Anticipated Phase 3 Data and Promising Trial ResultsJanuary 10, 2025 | markets.businessinsider.comInsider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK)January 10, 2025 | gurufocus.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 2,000 SharesCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,000 shares of the firm's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $49.32, for a total transaction of $98,640.00. Following the sale, the executive vice president now owns 116,071 shares in the company, valued at approximately $5,724,621.72. This represents a 1.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.January 10, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Reaches New 12-Month Low - Here's WhyCytokinetics (NASDAQ:CYTK) Hits New 1-Year Low - Here's WhyJanuary 10, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating on shares of Cytokinetics in a report on Friday.January 10, 2025 | marketbeat.comBank of America Securities Sticks to Their Hold Rating for Cytokinetics (CYTK)January 7, 2025 | markets.businessinsider.comCytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comKuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law FirmJanuary 4, 2025 | markets.businessinsider.comCytokinetics Inc (CYTK) Announces Stock Option Grants to New EmployeesJanuary 3, 2025 | gurufocus.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)January 3, 2025 | globenewswire.comCytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from AnalystsCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and twelve have given a buy recomJanuary 2, 2025 | marketbeat.comCytokinetics Aligns For U.S. Launch Amid HCM Market EvolutionDecember 31, 2024 | seekingalpha.comPrincipal Financial Group Inc. Cuts Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Principal Financial Group Inc. trimmed its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 30.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 273,082 shares of the biopharmaceutical company's stock after selling 120,497December 29, 2024 | marketbeat.comH.C. Wainwright Reaffirms Their Buy Rating on Cytokinetics (CYTK)December 24, 2024 | markets.businessinsider.comCytokinetics announces EMA has validated MAA for aficamtenDecember 24, 2024 | markets.businessinsider.comCytokinetics' aficamten application validated by EU regulatorsDecember 23, 2024 | msn.comCytokinetics Inc (CYTK) Advances Aficamten with EMA ValidationDecember 23, 2024 | gurufocus.comCytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyDecember 23, 2024 | globenewswire.comWhy Cytokinetics Stock Was a Nearly 5% Winner TodayDecember 20, 2024 | fool.comHC Wainwright Reiterates "Buy" Rating for Cytokinetics (NASDAQ:CYTK)HC Wainwright reaffirmed a "buy" rating and set a $120.00 target price on shares of Cytokinetics in a report on Friday.December 20, 2024 | marketbeat.comCytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater ChinaDecember 20, 2024 | globenewswire.comCalculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)December 19, 2024 | finance.yahoo.comFranklin Resources Inc. Sells 1,820,114 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Franklin Resources Inc. lessened its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 77.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 536,447 shares of the biopharmaceutical company's stock after selliDecember 19, 2024 | marketbeat.comCytokinetics price target raised to $82 from $80 at RBC CapitalDecember 18, 2024 | markets.businessinsider.comCytokinetics (NASDAQ:CYTK) Given New $82.00 Price Target at Royal Bank of CanadaRoyal Bank of Canada raised their price target on shares of Cytokinetics from $80.00 to $82.00 and gave the company an "outperform" rating in a report on Wednesday.December 18, 2024 | marketbeat.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells 742 Shares of StockDecember 17, 2024 | insidertrades.comGeode Capital Management LLC Raises Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Geode Capital Management LLC lifted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 4.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,848,584 shares of the biopharmaceutical company's stock after buyinDecember 17, 2024 | marketbeat.comWendall Wierenga Sells 742 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director Wendall Wierenga sold 742 shares of the business's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $48.61, for a total value of $36,068.62. Following the completion of the transaction, the director now owns 24,559 shares in the company, valued at approximately $1,193,812.99. This trade represents a 2.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.December 16, 2024 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $89,747.60 in StockDecember 13, 2024 | insidertrades.comInsider Sell: Fady Malik Sells 7,300 Shares of Cytokinetics Inc (CYTK)December 10, 2024 | gurufocus.comTwo Sigma Advisers LP Purchases New Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Two Sigma Advisers LP purchased a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 214,700 shares of the biopharmaceutical company's stoDecember 10, 2024 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from BrokeragesCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has been given an average recommendation of "Moderate Buy" by the sixteen research firms that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and twelve have assignedDecember 8, 2024 | marketbeat.comBNP Paribas Financial Markets Sells 15,629 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)BNP Paribas Financial Markets cut its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 27.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,292 shares of the biopharmaceutDecember 7, 2024 | marketbeat.comWhy Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?December 6, 2024 | finance.yahoo.comTruist Financial Sticks to Its Buy Rating for Cytokinetics (CYTK)December 6, 2024 | markets.businessinsider.comJanus Henderson Group PLC Has $60.40 Million Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Janus Henderson Group PLC grew its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 17.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,143,830 shares of thDecember 6, 2024 | marketbeat.comRedmile Group LLC Sells 14,751 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Redmile Group LLC lowered its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 13.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 97,116 shares of the biopharmaceutical company's stock after selling 14,751 shaDecember 5, 2024 | marketbeat.comMelqart Asset Management UK Ltd Cuts Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Melqart Asset Management UK Ltd lessened its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 27.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,212,258 shares of the biopharmaceutical company's stock afterDecember 4, 2024 | marketbeat.com Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTK Media Mentions By Week CYTK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTK News Sentiment▼0.430.44▲Average Medical News Sentiment CYTK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTK Articles This Week▼89▲CYTK Articles Average Week Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BeiGene News Summit Therapeutics News Genmab A/S News Viatris News Intra-Cellular Therapies News Moderna News Dr. Reddy's Laboratories News Catalent News Sarepta Therapeutics News Vaxcyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTK) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTK Stock Alerts